Mark Johnson, DO
Internal Medicine · Kissimmee, FLNPI 1740783554
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 31.8% of the total. 2025 is the largest year on record at $144, 8.5 times the $17 reported in 2020.
Across 25 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$157
- Bayer$58
- Pfizer$47
- Boston Scientific$40
- AbbVie$36
- Exact Sciences$34
- plus $122 from 5 others
What the payments were for
- Food & beverage$495100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $157 |
| Bayer | 3 | $58 |
| Pfizer | 2 | $47 |
| Boston Scientific | 1 | $40 |
| AbbVie(2 entities) | 2 | $36 |
| Exact Sciences | 2 | $34 |
| Abbott | 2 | $34 |
| Averitas Pharma Inc. | 1 | $25 |
| AstraZeneca | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Nevro Corp. | 1 | $20 |
How this compares
$495 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 12 | $142 |
| Atorvastatin Calcium | 19 | $93 |
| Tamsulosin Hcl | 12 | $82 |
| Lisinopril | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Kissimmee
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.